➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Harvard Business School
Johnson and Johnson
McKesson
Boehringer Ingelheim

Last Updated: April 20, 2021

DrugPatentWatch Database Preview

Loxapine - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for loxapine and what is the scope of patent protection?

Loxapine is the generic ingredient in five branded drugs marketed by Alexza Pharms, Teva Branded Pharm, Actavis Labs Ut Inc, Elite Labs Inc, Lannett Co Inc, Mylan, and Watson Labs, and is included in eleven NDAs. There are eighteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Loxapine has two hundred and twenty-six patent family members in twenty countries.

There are eight drug master file entries for loxapine. One supplier is listed for this compound.

Drug Prices for loxapine

See drug prices for loxapine

Recent Clinical Trials for loxapine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Lee's Pharmaceutical LimitedPhase 3
Mount Sinai Hospital, ChicagoPhase 4
University of ArkansasPhase 4

See all loxapine clinical trials

Medical Subject Heading (MeSH) Categories for loxapine

US Patents and Regulatory Information for loxapine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Teva Branded Pharm LOXITANE loxapine succinate CAPSULE;ORAL 017525-002 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial   Start Trial
Mylan LOXAPINE SUCCINATE loxapine succinate CAPSULE;ORAL 076762-002 Nov 1, 2004 AB RX No No   Start Trial   Start Trial   Start Trial
Elite Labs Inc LOXAPINE SUCCINATE loxapine succinate CAPSULE;ORAL 076868-003 Aug 4, 2005 AB RX No No   Start Trial   Start Trial   Start Trial
Mylan LOXAPINE SUCCINATE loxapine succinate CAPSULE;ORAL 076762-003 Nov 1, 2004 AB RX No No   Start Trial   Start Trial   Start Trial
Elite Labs Inc LOXAPINE SUCCINATE loxapine succinate CAPSULE;ORAL 076868-002 Aug 4, 2005 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for loxapine

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1389098 300609 Netherlands   Start Trial PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
1389098 C300609 Netherlands   Start Trial PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
1389098 CR 2013 00046 Denmark   Start Trial PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001-002 20130220
1389098 C01389098/01 Switzerland   Start Trial PRODUCT NAME: LOXAPINUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65461 13.12.2016
1389098 1390040-2 Sweden   Start Trial PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001 20130220
1389098 2013C/054 Belgium   Start Trial PRODUCT NAME: ADASUVE-LOXAPINE; AUTHORISATION NUMBER AND DATE: EU/1/13/823/001 20130225
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Medtronic
AstraZeneca
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.